Danya Institute Inc.

Opioids

Best Practices ~ Reentry

Best Practices for Successful Reentry From Criminal Justice Settings for People Living With Mental Health Conditions and/or Substance Use Disorders This guide examines the types of interventions that support successful reentry for adults with mental health conditions and/or substance use disorders who are leaving jail/prison.


National Recovery Month

National Recovery Month 2023 National Recovery Month 2022 National Recovery Month 2021 National Recovery Month 2020 National Recovery Month 2019 National Recovery Month 2018


ORN Regional Summit

Submit a request for similar summits, speakers, technical assistance, or trainings!!!    


ORN Event

   


Fentanyl Bill Passes House

From MedPage House Passes Bill to Address Fentanyl Overdoses — But critics say the HALT Fentanyl Act is the wrong way to approach the problem by Joyce Frieden The House passed a bill Thursday that proponents say is designed to reduce the number of people who become addicted to fentanyl, but opponents say it won’t […]


Opioid pain meds get new safety warning

From MedPage Today All Opioid Pain Meds to Get New Safety Warnings, FDA Says — Updated labeling to include warning about opioid-induced hyperalgesia The FDA is making several updates to the prescribing information for opioid pain medications to provide guidance on safe use, according to a Drug Safety Communicationopens in a new tab or window, […]


Tranq in Philly’s fentanyl supply

From CNN. Tranq has become a bigger part of Philly’s street fentanyl supply. The wounds left behind are killing people by Elle Reeve, Samantha Guff, and Deborah Brunswick Philadelphia (CNN) — What drug users and people who work with them in Philadelphia talk about is the smell. The smell of rotting flesh from open infected wounds. Some […]


FDA to Restrict Xylazine

From the FDA February 28, 2023 FDA Takes Action to Restrict Unlawful Import of Xylazine Agency Aims to Maintain Availability for Legitimate Use in Animals while Preventing Importation for Illicit Purposes Today, the U.S. Food and Drug Administration announced that it has taken action to restrict the unlawful entry of xylazine active pharmaceutical ingredients and finished dosage […]


FDA panel to review OTC Narcan

From Reuters U.S. FDA panel to review Emergent’s OTC opioid overdose drug Jan 10 (Reuters) – The U.S. health regulator said on Tuesday its advisory panel will meet on Feb. 15 to review Emergent Biosolutions Inc’s (EBS.N) over-the-counter (OTC) nasal spray to treat suspected opioid overdoses. Emergent is seeking the Food and Drug Administration’s (FDA)approval for the […]